Search results
Results from the WOW.Com Content Network
Astressin-B is a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of adrenocorticotropic hormone and cortisol. [1] It reduces the synthesis of adrenocorticotropic hormone and improves the sexual drive of rats under stressing conditions. [2] Astressin-B is able to delay the emptying of solid food in mice. [3]
A Corticotropin-releasing hormone antagonist (CRH antagonist) is a specific type of receptor antagonist that blocks the receptor sites for corticotropin-releasing hormone, also known as corticotropin-releasing factor (CRF), which synchronizes the behavioral, endocrine, autonomic, and immune responses to stress by controlling the hypothalamic-pituitary-adrenal axis (HPA axis). [1]
Antiestrogens include selective estrogen receptor modulators (SERMs) like tamoxifen, clomifene, and raloxifene, the ER silent antagonist and selective estrogen receptor degrader (SERD) fulvestrant, [6] [7] aromatase inhibitors (AIs) like anastrozole, and antigonadotropins including androgens/anabolic steroids, progestogens, and GnRH analogues.
Elacestrant was not McDonnell’s first attempt at bringing a breast cancer drug to market. In 1996, his lab developed a similar drug, etacstil, which was the first oral medication in this class ...
For premium support please call: 800-290-4726 more ways to reach us
Similarly, a cancer arising from malignant fat cells would be termed a liposarcoma. For some common cancers, the English organ name is used. For example, the most common type of breast cancer is called ductal carcinoma of the breast. Benign tumors (which are not cancers) are usually named using -oma as a suffix
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her announcement in August that she was diagnosed with DCIS, which stands ...
Owing to the causal relationship between H. pylori infection and gastric MALT lymphoma, identification of the infection is imperative. Histological examination of GI biopsies yields a sensitivity of 95% with five biopsies, [7] but these should be from sites uninvolved by lymphoma and the identification of the organism may be compromised by areas of extensive intestinal metaplasia.